CervoMed Beat Consensus Estimates

CervoMed (CRVO) reported a loss of $0.64 per share on revenue of $0.00 million for the second quarter ended June 2026. The consensus estimate was a loss of $0.87 per share on revenue of $0.30 million. The company beat consensus estimates by 26.44% while revenue fell 100.00% compared to the same quarter a year ago.

CervoMed Inc. is a clinical-stage biotechnology company advancing CNS-focused therapeutics for patients with a range of degenerative diseases of the brain. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant which inhibits p38MAP kinase alpha. CervoMed Inc., formerly known as Diffusion Pharmaceuticals Inc., is based in BOSTON.